Trial Profile
A Multicenter, Randomized, Double-blind, Placebo- and Active-Controlled Study Comparing the Safety and Analgesic Efficacy of ABT-110 to Placebo in Subjects with Chronic Low Back Pain
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2018
Price :
$35
*
At a glance
- Drugs ABT 110 (Primary) ; Naproxen
- Indications Back pain
- Focus Pharmacogenomic; Therapeutic Use
- 02 Mar 2013 Planned number of patients changed from 390 to 330 as reported by EudraCT.
- 12 Jan 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 29 Dec 2012 Additional lead trial centre identified as reported by European Clinical Trials Database.